AKT1 and colorectal carcinoma: The expression of p-EGFR and p-AKT decreased in CRC cells after DCZ0415 treatment suggesting that the anti-tumor effect of DCZ0415 was involved in the EGFR/AKT signaling pathway (Fig. 5G).